Percutaneous 17 β-estradiol in treatment of cancer of prostate
Authors:
- A. StegASA. Steg
- G. BenoitGBG. Benoit
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- HDL cholesterol and other lipids in coronary heart disease. The cooperative lipoprotein phenotyping study.Circulation, 1977
- Response of serum cholesterol and triglycerides to hormone treatment and the relation of pretreatment values to mortality in patients with prostatic cancerCancer, 1976
- Endocrine changes after diethylstilbestrol therapy Effects on prostatic neoplasm and pituitary-gonadal axisUrology, 1976
- Serum Lipid Levels and Thromboembolic Complications During Estrogen Therapy of Prostatic CancerScandinavian Journal of Urology and Nephrology, 1975
- The Coronary Drug Project. Findings leading to discontinuation of the 2.5-mg day estrogen group. The coronary Drug Project Research Group1973
- The veterans administration cooperative urological research group's studies of cancer of the prostateCancer, 1973
- In vitro effects of estrogens on rat prostatic 5α-reduction of testosteroneSteroids, 1973
- Inhibition of 5α-reductase activity of rat prostate by estradiol derivativesBiochimie, 1973
- CYTOLOGICAL DIAGNOSIS OF PROSTATIC TUMOURS BY TRANSRECTAL ASPIRATION BIOPSY: A PRELIMINARY REPORTBritish Journal of Urology, 1960
- Serologic Tests for Syphilis Following Smallpox Vaccination and Including Reiter Protein Complement Fixation Technic**From the Division of Dermatology, University of Minnesota; Division of Medical Laboratories, Minnesota Department of Health; University Student Health Service, University of Minnesota, Minneapolis, Minnesota.Journal of Investigative Dermatology, 1960